HK1203947A1 - Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol) - Google Patents
Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)Info
- Publication number
- HK1203947A1 HK1203947A1 HK15104491.9A HK15104491A HK1203947A1 HK 1203947 A1 HK1203947 A1 HK 1203947A1 HK 15104491 A HK15104491 A HK 15104491A HK 1203947 A1 HK1203947 A1 HK 1203947A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- halofuginol
- cosmetic
- derivatives
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Birds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586271P | 2012-01-13 | 2012-01-13 | |
PCT/US2013/021223 WO2013106702A1 (fr) | 2012-01-13 | 2013-01-11 | Dérivés d'halofuginol et leur utilisation dans des compositions cosmétiques et pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203947A1 true HK1203947A1 (en) | 2015-11-06 |
Family
ID=47844437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104491.9A HK1203947A1 (en) | 2012-01-13 | 2015-05-12 | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol) |
Country Status (7)
Country | Link |
---|---|
US (1) | US10155742B2 (fr) |
EP (1) | EP2802572B1 (fr) |
JP (1) | JP2015506363A (fr) |
AU (1) | AU2013207796B2 (fr) |
CA (1) | CA2861840C (fr) |
HK (1) | HK1203947A1 (fr) |
WO (1) | WO2013106702A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011530596A (ja) | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | tRNA合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
AU2013207796B2 (en) | 2012-01-13 | 2017-04-27 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
SI3159335T1 (sl) * | 2014-06-23 | 2020-07-31 | Daewoong Pharmaceutical Co., Ltd. | Nova heterociklična spojina |
KR102277538B1 (ko) | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
JP2019196307A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
US20190365760A1 (en) * | 2016-11-14 | 2019-12-05 | Keio University | A therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative or autoimmune disease, and a hypoxia inducing factor inhibitor |
US11708353B2 (en) | 2018-06-08 | 2023-07-25 | The General Hospital Corporation | Inhibitors of prolyl-tRNA-synthetase |
CN109134437B (zh) * | 2018-08-24 | 2021-05-25 | 中山大学 | 一种去氧常山酮类化合物及其制备方法和应用 |
WO2021163304A1 (fr) * | 2020-02-11 | 2021-08-19 | Tufts Medical Center, Inc. | Activation de récepteurs de neuropeptides sur des cellules dendritiques plasmacytoïdes pour traiter ou prévenir des maladies oculaires associées à la néovascularisation et à l'inflammation |
CN117693343A (zh) * | 2021-07-23 | 2024-03-12 | 株式会社大熊制药 | 用于预防或治疗系统性硬化症的药物组合物 |
WO2023140505A1 (fr) * | 2022-01-18 | 2023-07-27 | (주)큐라미스 | Composition destinée à la prévention ou au traitement de maladies neurodégénératives ou du motoneurone contenant de l'halofuginone en tant que principe actif |
CN114288300B (zh) * | 2022-01-29 | 2023-04-21 | 中国科学技术大学 | 常山酮在治疗和预防脂肪肝、肥胖的药物中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2694711A (en) | 1952-12-02 | 1954-11-16 | American Cyanamid Co | Quinazolone antimalarial compounds |
US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
DE2020234A1 (de) | 1970-04-25 | 1971-11-18 | Cassella Farbwerke Mainkur Ag | Basisch substituierte Derivate des 4(3H)-Chinazolinons |
GB1541463A (en) | 1975-10-11 | 1979-02-28 | Lion Dentifrice Co Ltd | Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase |
DE2934069A1 (de) | 1979-08-23 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Mittel gegen theileriosen und seine verwendung. |
US4762838A (en) | 1985-08-30 | 1988-08-09 | Pfizer Inc. | Quinazolin-4(3H)-one derivatives as anticoccidial agents |
US4999186A (en) | 1986-06-27 | 1991-03-12 | The Procter & Gamble Company | Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn |
US4937370A (en) | 1987-06-02 | 1990-06-26 | The Procter & Gamble Company | Novel chromophores, sunscreen compositions and methods for preventing sunburn |
US4725599A (en) | 1986-09-08 | 1988-02-16 | Pfizer Inc. | Heterocyclic ring fused pyrimidine-4 (3H)-ones as anticoccidial agents |
US4960764A (en) | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
US4800197A (en) | 1987-07-17 | 1989-01-24 | Richardson-Vicks Inc. | Anti-acne composition |
US4891227A (en) | 1988-02-02 | 1990-01-02 | Richardson-Vicks Inc. | Medicated cleansing pads |
US4891228A (en) | 1988-02-02 | 1990-01-02 | Richardson-Vicks Inc. | Medicated cleansing pads |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
US6446032B1 (en) | 1990-09-21 | 2002-09-03 | Massachusetts Institute Of Technology | Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5073372A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
CA2113229C (fr) | 1994-01-11 | 1999-04-20 | Mark Pines | Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes |
US5759833A (en) | 1994-05-27 | 1998-06-02 | Cubist Pharmaceuticals, Inc. | Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same |
US20020025316A1 (en) | 1995-08-18 | 2002-02-28 | Ferguson Mark Williams James | Pharmaceutical composition containing inhibitors of interferon-gamma |
US6028075A (en) | 1997-02-11 | 2000-02-22 | Pines; Mark | Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
AU737094B2 (en) | 1997-03-31 | 2001-08-09 | Agricultural Research Organization, Ministry Of Agricultural, State Of Israel | Treatment for pulmonary fibrosis |
WO2000009070A2 (fr) | 1998-08-13 | 2000-02-24 | Hadasit Medical Research Services And Development Company Ltd. | Inhibition de procedes lies a des lesions tissulaires |
WO2001013865A1 (fr) | 1999-08-20 | 2001-03-01 | Howard Murad | Compositions et methodes pharmaceutiques de reduction de l'apparition de la cellulite |
ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
JP3771128B2 (ja) | 2000-12-28 | 2006-04-26 | 独立行政法人科学技術振興機構 | フェブリフジンおよびフェブリフジン化合物の新規合成方法 |
US20050227935A1 (en) | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
EP1425385B1 (fr) | 2001-08-14 | 2009-03-18 | Washington University in St. Louis | Systemes et procedes de criblage de produits chimiques pharmaceutiques |
WO2004069793A2 (fr) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Nouveaux amines cycliques substitues en position 2 comme modulateurs du recepteur de detection de calcium |
CN1263753C (zh) | 2004-05-21 | 2006-07-12 | 厦门大学 | 一种合成常山碱与ru-19110中间体的方法 |
JP2008531547A (ja) * | 2005-02-23 | 2008-08-14 | コルガード バイオファーマシューティカルズ リミテッド | キナゾリノン誘導体であるハロフジノンの単離されたd−エナンチオマーの医薬組成物 |
WO2007058990A2 (fr) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapie a base d’inhibiteurs de cytokine |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
AU2007238816B2 (en) | 2006-04-10 | 2012-12-06 | President And Fellows Of Harvard College | Methods for modulating formation and progression of cellulite |
CA2683756A1 (fr) | 2006-04-14 | 2007-10-25 | Prana Biotechnology Limited | Procede de traitement de la degenerescence maculaire liee a l'age (amd) |
DK2044026T3 (da) | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
TW200836743A (en) | 2007-01-29 | 2008-09-16 | Xenon Pharmaceuticals Inc | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
US20080188498A1 (en) * | 2007-02-05 | 2008-08-07 | Radix Pharmaceuticals, Inc. | Pyridopyrimidinone compounds with antimalarial activity |
AU2008265600B2 (en) | 2007-06-21 | 2013-10-31 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
US20090123389A1 (en) | 2007-08-15 | 2009-05-14 | Malcolm Whitman | Methods for modulating Th17 cell development in the treatment and prevention of cellulite |
WO2009023267A2 (fr) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Procédé de modulation du développement et de l'expansion de cellules exprimant il-17 |
JP2011530596A (ja) * | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | tRNA合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
WO2010096170A2 (fr) | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition d'arnt synthétases et ses applications thérapeutiques |
US8357692B2 (en) * | 2010-06-20 | 2013-01-22 | Washington University | Methods of treatment of bone degenerative diseases |
AU2013207796B2 (en) | 2012-01-13 | 2017-04-27 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
-
2013
- 2013-01-11 AU AU2013207796A patent/AU2013207796B2/en active Active
- 2013-01-11 CA CA2861840A patent/CA2861840C/fr active Active
- 2013-01-11 WO PCT/US2013/021223 patent/WO2013106702A1/fr active Application Filing
- 2013-01-11 US US14/371,934 patent/US10155742B2/en active Active
- 2013-01-11 JP JP2014552326A patent/JP2015506363A/ja active Pending
- 2013-01-11 EP EP13708542.9A patent/EP2802572B1/fr not_active Not-in-force
-
2015
- 2015-05-12 HK HK15104491.9A patent/HK1203947A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2802572B1 (fr) | 2018-11-07 |
CA2861840C (fr) | 2020-12-15 |
EP2802572A1 (fr) | 2014-11-19 |
US20150057297A1 (en) | 2015-02-26 |
AU2013207796A1 (en) | 2014-08-07 |
CA2861840A1 (fr) | 2013-07-18 |
WO2013106702A1 (fr) | 2013-07-18 |
JP2015506363A (ja) | 2015-03-02 |
AU2013207796B2 (en) | 2017-04-27 |
US10155742B2 (en) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181364T1 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
HK1203947A1 (en) | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol) | |
IL236024A (en) | The history of benzimidazole-proline and its pharmaceutical preparations | |
HK1205690A1 (en) | Pharmaceutical composition and administration thereof | |
IL252566A0 (en) | Pharmacy preparations and methods | |
IL237839A0 (en) | History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them | |
IL235414A (en) | The history of pyrolotriazinone, their preparation and their pharmaceutical preparations | |
IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
IL244901A0 (en) | Derivatives of aminotetralin and aminoindan, pharmaceutical compositions containing them and their use in therapy | |
GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
HK1203050A1 (en) | Novel dosage and formulation | |
GB2504390B (en) | Nutraceutical and pharmaceutical composition | |
EP2685993A4 (fr) | Compositions pharmaceutiques et utilisation topique de celles-ci | |
IL235947A (en) | Solid state isonicotinamide history and their medicinal preparations | |
IL238059A0 (en) | History of pyrrolidine, and pharmaceutical preparations containing them | |
EP2874987A4 (fr) | Dérivés d'acide alpha- et gama-truxillique et leurs compositions pharmaceutiques | |
HK1204556A1 (zh) | 藥物組合物及使用該藥物組合物的準藥物化妝品 | |
HK1203496A1 (en) | Carbocyclic nucleosides and their pharmaceutical use and compositions | |
HK1203147A1 (en) | Cosmetic and pharmaceutical uses of saccharides | |
IL238826A (en) | History of imidazole - piperidinyl, their preparation and their pharmaceutical preparations | |
EP2926811A4 (fr) | Composition pharmaceutique comprenant de l'artéméther, préparation, et utilisation associée | |
EP2814448A4 (fr) | Agent gélifiant en vue d'une utilisation dans des compositions cosmétiques | |
GB201208315D0 (en) | Pharmaceutical methods and compositions | |
IL236870A0 (en) | The history of hydroxystatin, their preparation and pharmaceutical preparations containing them | |
AU2012900140A0 (en) | Pharmaceutical compositions and topical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230108 |